Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

Background Lapatinib has proven efficacy as monotherapy and in combination with capecitabine in patients with metastatic breast cancer (MBC) overexpressing HER2 and/or EGFR. Gemcitabine also has anti-tumor activity in MBC and a favourable toxicity profile. In this phase I study lapatinib and gemcita...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Noll, R., Smit, W. M., Wymenga, A. N. M., Boss, D. S., Grob, M., Huitema, A. D. R., Rosing, H., Tibben, M. M., Keessen, M., Rehorst, H., Beijnen, J. H., Schellens, J. H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648969/
https://www.ncbi.nlm.nih.gov/pubmed/26362459
http://dx.doi.org/10.1007/s10637-015-0281-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648969/
https://www.ncbi.nlm.nih.gov/pubmed/26362459
http://dx.doi.org/10.1007/s10637-015-0281-z

Ejemplares similares